KRAS and non-small cell lung carcinoma: Adagrasib was also approved in 2021 as second-line monotherapy for adults with KRAS-G12C mutated NSCLC (Nakajima et al., 2022) The KRYSTAL-1 Phase I trial (NCT03785249) was a dose escalation study where the patients with any solid tumour, harbouring a KRAS-G12C mutation received oral treatment and presented a mPFS of 6.5 months (Ou et al., 2022).